Luis Renta Rosa, MD
Cardiovascular Disease · Carolina, PRNPI 1265744734
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $69,560 of the $83,066 with a category attached, or 83.7%. Boehringer Ingelheim accounts for 82.5% of it on its own, with 17 other manufacturers making up the rest. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $305.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$69K
- Lilly USA, LLC$8K
- Medtronic$1K
- E.r. Squibb & Sons, L.L.C.$1K
- PBG Puerto Rico LLC$962
- AstraZeneca$770
- plus $3K from 12 others
What the payments were for
- Speaking & faculty fees$69,56084%
- Travel & lodging$3,4924%
- Food & beverage$10,00412%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 99 | $68,539 |
| Lilly USA, LLC | 6 | $7,835 |
| Medtronic | 8 | $1,044 |
| E.r. Squibb & Sons, L.L.C. | 19 | $1,019 |
| PBG Puerto Rico LLC | 49 | $962 |
| AstraZeneca | 20 | $770 |
| Johnson & Johnson | 26 | $740 |
| Amgen | 11 | $702 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $375 |
| Bayer | 2 | $246 |
| Pfizer Pharmaceuticals LLC | 3 | $222 |
| Merck | 2 | $192 |
| Boston Scientific | 4 | $115 |
| Abbott | 1 | $89 |
| Gilead | 5 | $74 |
| Novartis | 3 | $69 |
| Bayer Puerto Rico Inc. | 3 | $61 |
| Pfizer | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$75,319
- ELIQUIS$716
- Repatha$469
- Micra$441
- FARXIGA$378
- LifeVest$200
- COBALT DR MRI SURESCAN$171
- LINQ II$142
- Kerendia$121
- XARELTO$114
- BRILINTA$112
- SYMPLICITY G3$111
- Reveal LINQ$102
- STEGLATRO$100
How this compares
$83,066 in reported general payments places this provider in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 465 | $348,920 |
| EliquisApixaban | 232 | $168,857 |
| XareltoRivaroxaban | 85 | $72,455 |
| SynjardyEmpagliflozin/Metformin Hcl | 50 | $33,547 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 38 | $30,089 |
| Irbesartan | 993 | $23,108 |
| TrulicityDulaglutide | 21 | $22,416 |
| SynthroidLevothyroxine Sodium | 254 | $20,018 |
| Repatha SureclickEvolocumab | 32 | $18,669 |
| EntrestoSacubitril/Valsartan | 20 | $15,194 |
| FarxigaDapagliflozin Propanediol | 17 | $11,185 |
| Atorvastatin Calcium | 1,349 | $10,831 |
| Metoprolol Succinate | 683 | $9,550 |
| Rosuvastatin Calcium | 756 | $7,929 |
| Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide | 262 | $7,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr | $68,539 | $412,556553 claims |
| PfizerEliquis | $11 | $168,857232 claims |
| Johnson & JohnsonXarelto | $740 | $72,45585 claims |
| Lilly USA, LLCTrulicity | $7,835 | $22,41621 claims |
| NovartisEntresto | $69 | $15,19420 claims |
| AstraZenecaFarxiga | $770 | $11,18517 claims |
| MerckJanumet Xr | $192 | $6,99212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in Carolina
- Hector BanchsCarolina$41K
- Hector Mendez RiveraCarolina$10K
- Karen Rodriguez MaldonadoMayaguez$231K
- Jose NovoaBayamon$209K
- Manuel GuzmanSan Juan$203K
- Luis Rosado CarrilloGuaynabo$173K
- Jorge GonzalezCaguas$114K
- Luis GelyCaguas$89K
- Ramon PereaSan Juan$68K
- Denis Ruiz SerranoGuaynabo$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.